M

Myomo Inc
AMEX:MYO

Watchlist Manager
Myomo Inc
AMEX:MYO
Watchlist
Price: 5.09 USD 6.04% Market Closed
Market Cap: 154m USD
Have any thoughts about
Myomo Inc?
Write Note

Myomo Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Myomo Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
M
Myomo Inc
AMEX:MYO
Cash from Financing Activities
$5.2m
CAGR 3-Years
-15%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Cash from Financing Activities
$2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Cash from Financing Activities
$1.6B
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Cash from Financing Activities
$983m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
6%
Abbott Laboratories
NYSE:ABT
Cash from Financing Activities
-$6.4B
CAGR 3-Years
-13%
CAGR 5-Years
2%
CAGR 10-Years
-5%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Financing Activities
$70m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Myomo Inc
Glance View

Market Cap
154m USD
Industry
Health Care

Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.

MYO Intrinsic Value
3.7 USD
Overvaluation 27%
Intrinsic Value
Price
M

See Also

What is Myomo Inc's Cash from Financing Activities?
Cash from Financing Activities
5.2m USD

Based on the financial report for Sep 30, 2024, Myomo Inc's Cash from Financing Activities amounts to 5.2m USD.

What is Myomo Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-1%

Over the last year, the Cash from Financing Activities growth was -49%. The average annual Cash from Financing Activities growth rates for Myomo Inc have been -15% over the past three years , -1% over the past five years .

Back to Top